Information Provided By:
Fly News Breaks for May 23, 2018
AGIO
May 23, 2018 | 07:28 EDT
Citi analyst Mohit Bansal started Agios Pharmaceuticals with a Buy rating and $117 price target. Agios is a "unique" company with the potential to have multiple products on markets in next three years, Bansal tells investors in a research note. He believes the company has a "substantial opportunity" with its metabolic oncology and rare disease pipeline. The analyst has a "bull case" valuation of $170-$180 per share and takeover valuation of $180-$200 per share.
News For AGIO From the Last 2 Days
There are no results for your query AGIO